FI98455B - Förfarande för framställning av terapeutiskt aktiva indolderivat - Google Patents

Förfarande för framställning av terapeutiskt aktiva indolderivat

Info

Publication number
FI98455B
FI98455B FI930150A FI930150A FI98455B FI 98455 B FI98455 B FI 98455B FI 930150 A FI930150 A FI 930150A FI 930150 A FI930150 A FI 930150A FI 98455 B FI98455 B FI 98455B
Authority
FI
Finland
Prior art keywords
preparation
indole derivatives
therapeutically active
active indole
derivatives
Prior art date
Application number
FI930150A
Other languages
English (en)
Finnish (fi)
Other versions
FI930150A0 (sv
FI98455C (sv
FI930150A (sv
Inventor
Francesco G Salituro
Bruce M Baron
Original Assignee
Merrell Dow Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merrell Dow Pharma filed Critical Merrell Dow Pharma
Publication of FI930150A0 publication Critical patent/FI930150A0/sv
Publication of FI930150A publication Critical patent/FI930150A/sv
Application granted granted Critical
Publication of FI98455B publication Critical patent/FI98455B/sv
Publication of FI98455C publication Critical patent/FI98455C/sv

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/42—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurosurgery (AREA)
  • Medicinal Chemistry (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Anesthesiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
FI930150A 1990-07-16 1993-01-14 Förfarande för framställning av terapeutiskt aktiva indolderivat FI98455C (sv)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US55605790A 1990-07-16 1990-07-16
US55605790 1990-07-16
PCT/US1991/004253 WO1992001670A1 (en) 1990-07-16 1991-06-17 Excitatory amino acid antagonists
US9104253 1991-06-17

Publications (4)

Publication Number Publication Date
FI930150A0 FI930150A0 (sv) 1993-01-14
FI930150A FI930150A (sv) 1993-01-14
FI98455B true FI98455B (sv) 1997-03-14
FI98455C FI98455C (sv) 1997-06-25

Family

ID=24219725

Family Applications (1)

Application Number Title Priority Date Filing Date
FI930150A FI98455C (sv) 1990-07-16 1993-01-14 Förfarande för framställning av terapeutiskt aktiva indolderivat

Country Status (15)

Country Link
US (1) US5106847A (sv)
EP (1) EP0539503B1 (sv)
JP (1) JP3058688B2 (sv)
KR (1) KR0178469B1 (sv)
AT (1) ATE136295T1 (sv)
AU (1) AU646686B2 (sv)
CA (1) CA2087091C (sv)
DE (1) DE69118539T2 (sv)
DK (1) DK0539503T3 (sv)
ES (1) ES2088011T3 (sv)
FI (1) FI98455C (sv)
GR (1) GR3019689T3 (sv)
HU (1) HU216787B (sv)
NO (1) NO179249C (sv)
WO (1) WO1992001670A1 (sv)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5189054A (en) * 1990-11-02 1993-02-23 Merrell Dow Pharmaceuticals Inc. 3-amidoindolyl derivatives and pharmaceutical compositions thereof
US5318985A (en) * 1991-12-20 1994-06-07 Merrell Dow Pharmaceuticals Inc. Potentiation of NMDA antagonists
GB9208492D0 (en) * 1992-04-16 1992-06-03 Glaxo Spa Heterocyclic compounds
US5321012A (en) * 1993-01-28 1994-06-14 Virginia Commonwealth University Medical College Inhibiting the development of tolerance to and/or dependence on a narcotic addictive substance
USRE39300E1 (en) 1993-01-28 2006-09-19 Virginia Commonwealth University Medical College Of Virginia Inhibiting the development of tolerance to and/or dependence on an addictive substance
US5519048A (en) * 1993-05-27 1996-05-21 Merrell Pharmaceuticals Inc. 3-(indol-3-yl)-propenoic acid derivatives and pharmaceutical compositions thereof
TW280819B (sv) * 1993-11-17 1996-07-11 Sumitomo Pharma
US5783575A (en) * 1994-03-14 1998-07-21 Novo Nordisk A/S Antagonists, their preparation and use
US5696148A (en) * 1994-03-14 1997-12-09 Novo Nordisk A/S Indole compounds and their use in treating diseases of the central nervous system
US5563157B1 (en) * 1994-10-31 1999-02-02 Hoecst Marion Roussel Inc Heterocycle substituted propenoic acid derivatives and pharmaceutical compositions thereof
GB9502695D0 (en) * 1995-02-11 1995-03-29 Glaxo Spa Pharmaceutical composition
AU6514296A (en) * 1995-07-31 1997-02-26 Novo Nordisk A/S Heterocyclic compounds, their preparation and use
WO1998014427A1 (en) * 1996-09-30 1998-04-09 Hoechst Marion Roussel, Inc. Nmda (n-methyl-d-aspartate) antagonists
ES2230676T3 (es) 1997-03-14 2005-05-01 Smithkline Beecham Corporation Nuevos indolcarboxamidas, composiciones farmaceuticas y procedimientos de inhibicion de la calpaina.
US5922752A (en) * 1997-06-11 1999-07-13 Hoechst Marion Roussell, Inc. NMDA (n-methyl-d-aspartate) antagonists
JP2005506292A (ja) * 2001-03-08 2005-03-03 エモリー　ユニバーシティ ｐＨに依存するＮＭＤＡレセプターアンタゴニスト
WO2003039540A2 (en) * 2001-11-09 2003-05-15 Sepracor Inc. D-amino acid oxidase inhibitors for learning and memory
US7884124B2 (en) 2006-06-30 2011-02-08 Sepracor Inc. Fluoro-substituted inhibitors of D-amino acid oxidase
CN103058957A (zh) 2007-06-29 2013-04-24 埃莫里大学 用于神经保护的nmda受体拮抗剂

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4960786A (en) * 1989-04-24 1990-10-02 Merrell Dow Pharmaceuticals Inc. Excitatory amino acid antagonists
JPH0347123A (ja) * 1989-05-05 1991-02-28 G D Searle & Co インドール―２―カルボキシレート化合物類を含有するｃｎｓ疾患治療用組成物
EP0548250B1 (en) * 1990-09-10 1996-03-27 Rhone-Poulenc Rorer International (Holdings) Inc. Substituted bicyclic aryl compounds exhibiting selective leukotriene b4 antagonist activity
WO1993005020A1 (en) * 1991-09-06 1993-03-18 Merck & Co., Inc. Indoles as inhibitors of hiv reverse transcriptase

Also Published As

Publication number Publication date
GR3019689T3 (en) 1996-07-31
HUT67237A (en) 1995-03-28
AU8290891A (en) 1992-02-18
CA2087091A1 (en) 1992-01-17
DE69118539T2 (de) 1996-09-19
FI930150A0 (sv) 1993-01-14
EP0539503B1 (en) 1996-04-03
ES2088011T3 (es) 1996-08-01
EP0539503A4 (sv) 1994-03-23
WO1992001670A1 (en) 1992-02-06
JP3058688B2 (ja) 2000-07-04
KR0178469B1 (ko) 1999-03-20
AU646686B2 (en) 1994-03-03
NO930035L (no) 1993-01-07
FI98455C (sv) 1997-06-25
NO930035D0 (no) 1993-01-07
NO179249B (no) 1996-05-28
DK0539503T3 (da) 1996-05-13
CA2087091C (en) 2001-09-11
FI930150A (sv) 1993-01-14
NO179249C (no) 1996-09-04
US5106847A (en) 1992-04-21
EP0539503A1 (en) 1993-05-05
HU9300100D0 (en) 1993-04-28
JPH05508857A (ja) 1993-12-09
HU216787B (hu) 1999-08-30
ATE136295T1 (de) 1996-04-15
DE69118539D1 (de) 1996-05-09

Similar Documents

Publication Publication Date Title
FI98455B (sv) Förfarande för framställning av terapeutiskt aktiva indolderivat
FI104170B1 (sv) Förfarande för framställning av terapeutiskt användning 3-aminopyrazolderivat
NO180749C (no) Analogifremgangsmåte for fremstilling av terapeutisk aktive benzimidazolsubstituerte derivater
FI98454B (sv) Förfarande för framställning av terapeutiskt aktiva 3-indolyltioacetatderivat
SE9003057D0 (sv) New process
DE69127755D1 (de) Okulare hypotensive 2-dekarboxyl-2-aminoalkyl-prostaglandine
DE69230224D1 (de) Potenzierung von nmda-antagonisten
EE03027B1 (et) Meetod 8-klorokinolooni derivaatide valmistamiseks
FI103202B1 (sv) Förfarande för framställning av terapeutiskt användbara 4-sulfonamido-1,4-dihydrokinolinderivat
FI906084A (sv) Förfarande för framställning av nya terapeutiskt användbara 5-(2-metyl-4,4,4-trifluorbutylkarbamoyl)indolderivat
NO178375C (no) Analogifremgangsmåte for fremstilling av terapeutisk aktive NMDA-antagonister
NO880922D0 (no) Fremgangsmaate for fremstilling av farmakologisk aktive benzodioksolderivater.
FI910448A (sv) Förfarande för framställning av terapeutiskt användbara 1,2,3,3a,8,8a-hexahydro-1,3a,8-trimetyl-pyrrolo/2,3-b/indolderivat
FI97388B (sv) Förfarande för framställning av heterocykliska NMDA-antagonister
GR1001309B (el) Μεθοδος παρασκευης παραγωγου ενωσεως της διχλωροανιλινης.
NO178782C (no) Fremgangsmåte for fremstilling av et farmasöytisk akseptabelt gelpreparat
NO903397L (no) Analogifremgangsmaate for fremstilling av terapeutisk virksomme derivater av protocatechualdehyd.
NO174393C (no) Analogifremgangsmåte for fremstilling av terapeutisk aktive 6-metyl-19-nor-pregna-4,6-diener som er 17 eventuelt 21-alkylert
FI970396A (sv) Förfarande för framställning av terapeutiskt aktiva iminosubstituerade cyklopent(b)indolderivat
NO961910D0 (no) Fremgangsmåte for fremstilling av terapeutisk aktive polyamider
GR930100339A (el) Μέ?οδος για την παρασκευή δικυκλικών αμιδινουδραζονών.

Legal Events

Date Code Title Description
BB Publication of examined application